Sponsors (35)
Introduced February 12, 2025 by Catherine Marie Cortez Masto · Last progress February 12, 2025
The bill standardizes and tightens federal control over xylazine—improving enforcement clarity and public-health data—but does so at the cost of higher compliance burdens, possible reduced access to legitimate veterinary/medical uses, and expanded criminal penalties that may worsen disparities and divert focus from treatment.
Law enforcement, prosecutors, and courts gain a clear statutory definition and updated authority over xylazine, reducing ambiguity in investigations, seizures, and prosecutions.
Public-health officials and policymakers will receive standardized reporting and improved federal data on xylazine prevalence and sources, enabling better-targeted prevention, surveillance, and treatment planning.
Veterinarians, animal-care providers, farmers, and similar users can continue lawful xylazine use during a transition period (including a 60‑day registration window and one-year delays on some labeling/distribution rules), avoiding immediate disruption to animal care and supply chains.
People prosecuted for xylazine-related offenses and communities with high drug enforcement are likely to face expanded criminal exposure and tougher federal penalties, increasing prosecutions and incarceration risk.
Patients, veterinarians, and animal owners may face reduced access to legitimate xylazine-containing medications and higher costs as tighter controls and new compliance burdens limit availability.
Manufacturers, distributors, pharmacies, and veterinary providers will incur higher compliance costs (registration, recordkeeping, security, new labeling/packaging), which could raise prices, reduce suppliers, and strain small businesses.
Based on analysis of 7 sections of legislative text.
Places xylazine — a veterinary sedative increasingly found in the illegal drug supply — into Schedule III of the federal Controlled Substances Act, defines the term, and sets out transitional rules for manufacturers, practitioners, and labeling. It directs federal agencies to expedite related regulatory actions, asks the Sentencing Commission to review penalties for offenses involving xylazine, and requires two reports to Congress on illicit xylazine use and trafficking. Delays some new compliance obligations (practitioner registration/records for 60 days; labeling/packaging/distribution for 1 year) and exempts certain approved animal drug products from being treated as controlled substances for ultimate-user registration purposes.